Liposomes have been used as carriers of therapeutic agents and have been particularly successful for treating parasitic and fungal infections involving macrophages (1) . For example, liposome-encapsulated antimonial drugs are in excess of 700 times more effective than nonencapsulated drugs in the treatment of experimental leishmaniasis (1, 2) . In liposome-encapsulated form, amphotericin B and other antimicrobial drugs (5, 10, 12, 16, 21) and immunomodulators (9, 19) have been utilized for the treatment of microbial infections. This led us to a comparison of the chemotherapeutic efficacy of aqueous ribavirin (RIB) and liposome-encapsulated RIB (L-RIB) against Rift Valley fever virus (RVFV) infection in mice. In this infection, virus replication initially occurs within the fixed macrophages of the liver (Kupffer cells) and later in reticuloendothelial cells of other visceral organs (17) .
MATERIALS AND METHODS
Drug. RIB (1-,-D-ribofuranosyl-2,4-triazole-3-carboxamide) and 14C-labeled RIB (100 ,uCi/0.43 mg) containing 14C label in the 3 position of the triazole ring (specific activity, 56.3 mCi/mol) were purchased from ICN Pharmaceuticals, Irvine, Calif.
Preparation of aqueous drug. For tissue distribution studies in normal mice, free RIB was prepared by dissolving unlabeled and 14C-labeled RIB in sterile water in a ratio of 200:1 and then diluting it in saline to a final concentration of 1 mg/ml. For efficacy studies in RVFV-infected mice, free (unlabeled) RIB was dissolved in sterile saline to yield the desired dose in a volume equivalent to 1% body weight.
Liposome preparation. distribution studies in normal mice), 240 mg of cold RIB and 0.34 mg of labeled RIB were mixed, and 22 ml of the combination (75 mglml) was used to hydrate a dry shell of lipids obtained previously by coating the flask with 4.4 ml each of 50 mM dipalmitoyl phosphatidylcholine, 37.5 mM cholesterol, and 5.5 mM dicetyl phosphate. The final concentration of encapsulated RIB was calculated either from radioactive measurements or by determination of optical densities measured spectrophotometrically at a wavelength of 206 nm by use of a standard curve after dissolving encapsulated RIB in isopropyl alcohol. By either method, liposomes contained approximately 16 mg of drug per ml, representing a 20% encapsulation efficiency. For antiviral efficacy studies, 75 mg of cold RIB per ml was encapsulated as described above. The respective encapsulation yields of the two batches were 19 and 22%. Empty liposomes were prepared as described above, with sterile water.
Mice. Female Swiss Webster mice, 5 or 12 weeks of age, were used as specified. The mice were purchased from Harlan Sprague-Dawley, Walkersville, Md.
Virus. The Zagazig 501 strain of RVFV was isolated in Egypt during the 1977 epidemics (14) . The virus was grown on Vero cells and enumerated by counting PFU under agar (14) . In the efficacy studies, challenge doses of 250 or 5,000 PFU were employed as indicated. Treatment with a 10-mg/kg dose of L-RIB resulted in a survival rate, 20 days after infection, that was fivefold higher than that achieved with a 10-mg/kg dose of liposomne-free RIB (Fig. 2) . This low-dose (10-mg/kg) regimen of L-RIB resulted in a surviyal rate after 12 days that was equivalent to that achieved in experimental groups receiving 25 and 50 mg of RIB per kg. Because of the short treatment schedule, the therapeutic effect was reduced when examined beyond day 12. Treatment with emnpty drug-free 1iposomes (equivalent to the amount injected with 50 mg of L-RIB per kg) was not effective. ' Efficacy of longer treatment against a higher dose of RVFV. Mice were inoculated with 5,000 PFU of RVFV and treated over a course of 11 days (Fig. 3) . Treatment, consisting of doses of 12.5, 25, or 50 mg of L-RIB, RIB, saline, or empty liposomes per kg, was initiated within 60 min after inoculation and spaced as indicated by the arrows in Fig. 3 . RIB was significantly less effective against the higher dose of 5,000 PFU thlan against 250 PFU, even though the treatment was administered for an extended schedule (up to 11 days). Because of the increased total drug load, 12-week-old mice were employed in the study, as they have a better tolerance than younger mice for larger amounts of RIB. The high RVFV dose resulted in the death of all untreated mice by (Fig. 1) . Therapy with empty liposomes containing 1.5 ,umol of phospholipid, an amount equivalent to that delivered with 50 mg of L-RIB per kg, had no effect beyond the saline controls (data not shown). DISCUSSION RVFV infection has long been a major epizootic pathogen in sub-Saharan Africa (14) . In humans, this agent typically causes self-limiting febrile illness, and approximately 1% of the reported cases progress to fatal hemorrhagic fever or encephalitis (7) . Experimental RVFV infection in mice results in fatal hepatitis or encephalitis in virtually all animals (6, 17) . High doses of RIB have been used successfully to treat experimental RVFV infections in several strains of mice (11, 20) . Treatment failures occur at low drug doses, however, resulting in death due to either hepatitis or, a few days later, encephalitis.
This report describes the first successful in vivo use of a liposome-encapsulated compound for the treatment of a lethal virus-induced infection in mice. The rationale for this approach was based on the known propensity for liposomes to be phagocytosed by macrophages of the liver, spleen, and lung (1, 2, 22) , where RVFV is known to replicate (18) .
In the present study, we demonstrated that L-RIB had a high level of efficacy against a high dose of RVFV under conditions in which the same dose of free drug was completely ineffective in terms of long-term survivors. The efficacy of a low dose of L-RIB equalled that of a fivefoldhigher dose of the aqueous drug when the amount of the virus challenge was much lower. This therefore demonstrates that RVFV infection in mice can be accessible to treatment by liposomal drug carriers.
With respect to tissue distribution, liposomal delivery of RIB substantially increased the levels obtained in liver, spleen, and lung 1 h after injection. Proportionally, fivefold more drug was distributed into the three major target organs by L-RIB than by aqueous RIB. A previously published study in rodents has demonstrated that a peak drug concentration occurs at 30 min in tissues (8) . In that study, the RIB concentration was already slightly diminished after 1 h, and RIB had completely disappeared from the tissues at 24 h (8) .
The liposome-mediated increase in RIB concentration in the spleen is of particular importance, since the virus spreads from the liver into the reticuloendothelial cells of the spleen (17) . The (15) , and theoretically at least one virus particle will kill the host. It is therefore assumed that the presence of a higher amount of RIB in the target organs (as was the case with L-RIB in normal mice) might be translated to increased antiviral activity in vivo. The biological activity of RIB has been reviewed extensively (4, 11) 
